Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $618.79 million. The enterprise value is $784.61 million.
| Market Cap | 618.79M |
| Enterprise Value | 784.61M |
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 6.97 million shares outstanding. The number of shares has increased by 23.03% in one year.
| Current Share Class | 6.97M |
| Shares Outstanding | 6.97M |
| Shares Change (YoY) | +23.03% |
| Shares Change (QoQ) | -1.48% |
| Owned by Insiders (%) | 28.29% |
| Owned by Institutions (%) | 22.15% |
| Float | 3.96M |
Valuation Ratios
The trailing PE ratio is 8.47 and the forward PE ratio is 4.76.
| PE Ratio | 8.47 |
| Forward PE | 4.76 |
| PS Ratio | 0.71 |
| Forward PS | 0.61 |
| PB Ratio | 1.91 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | 2.56 |
| P/OCF Ratio | 2.49 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.90, with an EV/FCF ratio of 3.25.
| EV / Earnings | 11.08 |
| EV / Sales | 0.90 |
| EV / EBITDA | 1.90 |
| EV / EBIT | 2.00 |
| EV / FCF | 3.25 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.83.
| Current Ratio | 3.41 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 1.46 |
| Interest Coverage | 17.67 |
Financial Efficiency
Return on equity (ROE) is 58.94% and return on invested capital (ROIC) is 47.43%.
| Return on Equity (ROE) | 58.94% |
| Return on Assets (ROA) | 31.18% |
| Return on Invested Capital (ROIC) | 47.43% |
| Return on Capital Employed (ROCE) | 51.62% |
| Weighted Average Cost of Capital (WACC) | 11.41% |
| Revenue Per Employee | $994,610 |
| Profits Per Employee | $80,442 |
| Employee Count | 880 |
| Asset Turnover | 1.11 |
| Inventory Turnover | 141.34 |
Taxes
In the past 12 months, Nutex Health has paid $64.42 million in taxes.
| Income Tax | 64.42M |
| Effective Tax Rate | 26.32% |
Stock Price Statistics
The stock price has increased by +92.29% in the last 52 weeks. The beta is 2.00, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.00 |
| 52-Week Price Change | +92.29% |
| 50-Day Moving Average | 130.24 |
| 200-Day Moving Average | 120.56 |
| Relative Strength Index (RSI) | 36.14 |
| Average Volume (20 Days) | 204,691 |
Short Selling Information
The latest short interest is 927,725, so 13.31% of the outstanding shares have been sold short.
| Short Interest | 927,725 |
| Short Previous Month | 878,743 |
| Short % of Shares Out | 13.31% |
| Short % of Float | 23.43% |
| Short Ratio (days to cover) | 4.57 |
Income Statement
In the last 12 months, Nutex Health had revenue of $875.26 million and earned $70.79 million in profits. Earnings per share was $10.48.
| Revenue | 875.26M |
| Gross Profit | 471.31M |
| Operating Income | 392.63M |
| Pretax Income | 244.78M |
| Net Income | 70.79M |
| EBITDA | 413.16M |
| EBIT | 392.63M |
| Earnings Per Share (EPS) | $10.48 |
Balance Sheet
The company has $185.57 million in cash and $351.39 million in debt, with a net cash position of -$165.82 million or -$23.80 per share.
| Cash & Cash Equivalents | 185.57M |
| Total Debt | 351.39M |
| Net Cash | -165.82M |
| Net Cash Per Share | -$23.80 |
| Equity (Book Value) | 423.44M |
| Book Value Per Share | 46.49 |
| Working Capital | 380.90M |
Cash Flow
In the last 12 months, operating cash flow was $248.13 million and capital expenditures -$6.84 million, giving a free cash flow of $241.29 million.
| Operating Cash Flow | 248.13M |
| Capital Expenditures | -6.84M |
| Free Cash Flow | 241.29M |
| FCF Per Share | $34.63 |
Margins
Gross margin is 53.85%, with operating and profit margins of 44.86% and 8.09%.
| Gross Margin | 53.85% |
| Operating Margin | 44.86% |
| Pretax Margin | 27.97% |
| Profit Margin | 8.09% |
| EBITDA Margin | 47.20% |
| EBIT Margin | 44.86% |
| FCF Margin | 27.57% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.03% |
| Shareholder Yield | -23.03% |
| Earnings Yield | 11.44% |
| FCF Yield | 38.99% |
Analyst Forecast
The average price target for Nutex Health is $252.50, which is 184.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $252.50 |
| Price Target Difference | 184.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Nutex Health has an Altman Z-Score of 3.15 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.15 |
| Piotroski F-Score | 7 |